# OnCo record nct04895436 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04895436/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04895436", "NCT04895436" ;
  schema:name "Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)"@en ;
  schema:alternateName "ReVenG"@en ;
  schema:description "A phase 2 trial of Venetoclax and Obinutuzumab in chronic lymphocytic leukaemia, run by AbbVie, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04895436/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04895436> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2022-03-28" ;
  onco:cancers <https://onco.cc/cancers/cll/> ;
  onco:technologies <https://onco.cc/technologies/bcl2-inhibitors/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/obinutuzumab/> ;
  onco:companies <https://onco.cc/companies/abbvie/> .